was $4.1 million. A substantial portion of the deferred tax assets we utilized comprised cumulative deductions for stock options in excess of book expense. Under income tax accounting rules, that portion of tax benefits attributable to such deductions must be recorded as an adjustment to equity versus a reduction of income tax expense. In the three months ended June 30, 2012, the tax benefits from such stock-based awards were $12.7 million, which we recorded as an equity adjustment to additional paid-in capital. After the equity adjustment, we recorded $16.8 million of income tax expense in the statement of comprehensive income during the three months ended June 30, 2012. The $16.8 million income tax expense consists of the $4.1 million current income tax liability plus a $12.7 million non-cash adjustment that was recorded to equity.
We intend to continue to pursue patent monetization alternatives for certain other patents remaining in our patent portfolio. We are unable to predict the size or the timing of any future potential transactions involving such patents or whether such transactions will be completed.
We believe that the patent sale we completed in the second quarter of 2012 will have no material impact on our biometrics and imaging and DSL service assurance product lines, which will continue after the patent sale.
Additional information regarding second quarter operating results is presented below:
Product revenue was $4.0 million in the second quarters of 2011 and 2012. Higher biometrics and imaging software revenue was offset by a decrease in DSL service assurance hardware revenue.
The increase in biometrics and imaging software revenue was primarily due to several larger-sized license transactions in the current year quarter as compared to last year. The decrease in hardware revenue was mainly attributable to our decision in January 2012 to shut down our DSL service assurance hardware product line. We now Page: 1 2 3 4 5 6 Related biology news :1
. Aware, Inc. Reports First Quarter 2012 Financial Results2
. GEN reports on growth of tissue engineering revenues3
. BGI reports the completed sequence of foxtail millet genome4
. Radiologists study necessity of additional imaging recommendations in PET/CT oncologic reports5
. NOAA plankton surveys, second longest in the North Atlantic, add to new global effort6
. U-M forecasters predict second-smallest Gulf of Mexico dead zone7
. Second Middle East & Africa Osteoporosis Meeting to take place in Jordan8
. Second-generation drug used for hypertension aids heart function independent of blood pressure9
. BioLife Solutions Announces 7th Consecutive Quarter of Record Revenue10
. One-quarter of grouper species being fished to extinction11
. Study examines autism law, financial burdens